Lim, Wei-Wen
Corden, Ben
Ng, Benjamin
Vanezis, Konstantinos
D’Agostino, Giuseppe
Widjaja, Anissa A.
Song, Wei-Hua
Xie, Chen
Su, Liping
Kwek, Xiu-Yi
Tee, Nicole G. Z.
Dong, Jinrui
Ko, Nicole S. J.
Wang, Mao
Pua, Chee Jian
Jamal, Muhammad H.
Soh, Beeyong
Viswanathan, Sivakumar
Schafer, Sebastian
Cook, Stuart A.
Funding for this research was provided by:
National Medical Research Council (NMRC/OFYIRG/0053/2017, MOH-OFYIRG18nov-0003, NMRC/STaR/0029/2017)
Heart Research UK (RG2657/17/19)
Article History
Received: 3 June 2020
Accepted: 16 September 2020
First Online: 20 October 2020
Competing interests
: S.A.C. and S.S. are co-inventors of the patent applications ‘Treatment of fibrosis’ (WO/2017/103108) and ‘IL-11 antibodies’ (WO/2018/109174). S.A.C., S.S., W.W.L. and B.N are co-inventors of the patent application ‘Treatment of SMC mediated disease’ (WO/2019/073057). S.A.C. and S.S. are co-founders and shareholders of Enleofen Bio PTE LTD, a company (which S.A.C. is a director of) that develops anti-IL11 therapeutics. All other authors declare no competing interests.